The EGFR-targeting antibody cetuximab (CTX) combined with radiotherapy has been proven effective for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.